Drugs / RPH-051
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07386938 | Aug 2024 → Oct 2025 overdue | breast cancer | R-Pharm | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPH-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07386938 ↗ |
| Route | Intravenous | “RPH-051 will be administered on Day 1 of each 21-day cycle, with a loading dose of 840 mg given as a 60-minute intravenous infusion in Cycle 1, followed by a maintenance dose...” NCT07386938 ↗ |